WINNIPEG, MANITOBA--(MARKET WIRE)--Sep 4, 2007 -- Kane Biotech's (CDNX:KNE.V - News) Chief Scientific Officer prepares a report on the recent research related to the potential application of the Company's DispersinB(TM) technology together with bacteriophage for biofilm-based chronic wound treatment. There is increasing evidence that biofilm formation in wounds is the main reason for the failure of chronic wounds to heal, because biofilm-embedded bacteria are resistant to antibiotic/antimicrobial treatments and also to host immune responses.
